TVTX · Categories · Upgrades
TVTX - Analyst upgrades
Travere Therapeutics Inc. (TVTX) analyst upgrades - real-time wire coverage filtered to Upgrades only.
Recent Upgrades for TVTX
- Travere Therapeutics upgraded by Piper Sandler with a new price targetPiper Sandler upgraded Travere Therapeutics from Neutral to Overweight and set a new price target of $49.00
- Travere Therapeutics upgraded by Wells Fargo with a new price targetWells Fargo upgraded Travere Therapeutics from Equal Weight to Overweight and set a new price target of $27.00 from $9.00 previously
- Travere Therapeutics upgraded by Guggenheim with a new price targetGuggenheim upgraded Travere Therapeutics from Neutral to Buy and set a new price target of $25.00
- Travere Therapeutics upgraded by Citigroup with a new price targetCitigroup upgraded Travere Therapeutics from Neutral to Buy and set a new price target of $10.00 from $7.00 previously
- Travere Therapeutics upgraded by Bryan GarnierBryan Garnier upgraded Travere Therapeutics from Sell to Neutral
- Travere Therapeutics upgraded by Wedbush with a new price targetWedbush upgraded Travere Therapeutics from Neutral to Outperform and set a new price target of $30.00